Notes
2016 euros
Reference
Casado LF, et al. Cost-Utility of Idelalisib in Combination with Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY72, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/77652?pdfid=52098
Rights and permissions
About this article
Cite this article
Idelalisib plus rituximab cost effective for CLL in Spain. PharmacoEcon Outcomes News 793, 17 (2017). https://doi.org/10.1007/s40274-017-4577-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4577-4